Table 1

Demographics and baseline clinical characteristics of patients with MDR-TB, 2006–2016. Percentages may add up to >100% due to rounding

Total
n (%)
Community based
n (%)
Hospital based
n (%)
P values
582288 (49)294 (51)
Sex
 Female213 (37)117 (41)96 (33)
 Male369 (63)171 (59)198 (67)0.046
Age
 Median (IQR)45 (33–55)45 (33–56)45 (34–53)0.52
 <153 (0.5)1 (0.4)2 (0.7)
 15–2991 (16)44 (15)47 (16)
 30–49267 (46)128 (44)139 (47)
 50+221 (38)115 (40)106 (36)0.76
HIV status
 Positive117 (20)53 (18)64 (22)
 Negative465 (80)235 (82)230 (78)0.31
ART (HIV+ only)
 Yes110 (94)50 (94)60 (94)
 No7 (6)3 (6)4 (6)0.89
Median BMI (IQR)17.2 (15.2–19)17.4 (15.6–19.4)16.9 (15–18.8)0.04
Resistance pattern
 GXP only (RIF)217 (37)161 (56)56 (19)
 INH+RIF only108 (19)37 (13)71 (24)
 INH+RIF+253 (43)87 (30)166 (57)
 XDR4 (0.7)3 (1)1 (0.3)<0.001
TB history
 No prior TB treatment276 (47)146 (51)130 (44)
 Prior TB treatment306 (53)142 (49)164 (56)0.11
Site of TB
 Pulmonary562 (97)282 (98)280 (95)
 Extrapulmonary16 (3)3 (1)13 (4)
 Pulmonary and extrapulmonary4 (0.7)3 (1)1 (0.3)0.03
  • ART, antiretroviral therapy; BMI, body mass index; GXP, GeneXpert MTB/RIF; INH, isoniazid; INH+RIF+, additional drug resistance beyond INH and RIF, not XDR; MDR-TB, multidrug-resistant tuberculosis; RIF, rifampicin; XDR, extensively drug-resistant TB.